Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke

Neurologia Medico-Chirurgica

Volumn 51, Issue 12, 2011, Pages 819-824

  Fujita, Keishi ^a   Komatsu, Yoji ^b   Sato, Naoaki ^c   Higuchi, Osamu ^d   Kujiraoka, Yuji ^e   Kamezaki, Takao ^a   Suzuki, Kensuke ^f   Matsumura, Akira ^g  

^a Department of Neurosurgery   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^c Kobari General Hospital   (Japan)

^d Department of Neurosurgery   (Japan)

^e IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Acute ischemic stroke; Aspirin; Cilostazol; Progressive stroke; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; BAYASPIRIN; CILOSTAZOL; CLOPIDOGREL; NORPHENAZONE; OZAGREL; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATOCHEZIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SCORING SYSTEM; SYMPTOMATOLOGY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STROKE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84455195508     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.51.819     Document Type: Article

References (31)

1. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002
2. Birschel P, Ellul J, Barer D: Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis 17: 242-252, 2004
3. Britton M, Roden A: Progression of stroke after arrival at hospital. Stroke 16: 629-632, 1985
4. Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 349: 79-83, 1997
5. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R: Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31: 1240-1249, 2000
6. Chinese Acute Stroke Trial Collaborative Group: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349: 1641-1649, 1997
7. Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 40: 1865-1869, 1990
8. Davalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J: Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 30: 2631-2636, 1999
9. DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ, Kelly BJ: Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. Stroke 30: 1208-1212, 1999
10. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9: 147-157, 2000
11. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349: 1569-1581, 1997
12. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS: Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36: 782-786, 2005
13. Leira R, Davalos A, Aneiros A, Serena J, Pumar JM, Castillo J: Headache as a surrogate marker of the molecular mechanisms implicated in progressing stroke. Cephalalgia 22: 303-308, 2002
14. Lubart E, Leibovitz A, Baumoehl Y, Klein C, Gil I, Abramovitz I, Gurevitz A, Habot B: Progressing stroke with neurological deterioration in a group of Israeli elderly. Arch Gerontol Geriatr 41: 95-100, 2005
15. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J: Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25: 2220-2226,1994
16. Mandava P, Lick SD, Rahman MA, Langsjoen H, Reddy KV, Nelson J, Kent TA: Initial safety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis 19: 276-278, 2005
17. Meyer DM, Albright KC, Allison TA, Grotta JC: LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis 17: 26-29, 2008
18. Multicentre Acute Stroke Trial-Italy (MAST-I) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346: 1509-1514, 1995
19. Pereira AC, Brown MM: Aspirin or heparin in acute stroke. Br Med Bull 56: 413-421, 2000
20. Röden-Jüllig A, Britton M, Malmkvist K, Leijd B: Aspirin in the prevention of progressing stroke: a randomized controlled study. J Intern Med 254: 584-590, 2003
21. Sandercock P, Gubitz G, Foley P, Counsell C: Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev (2): CD000029, 2003
22. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Davalos A: Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 32: 1154-1161, 2001
23. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968, 2010
24. Shinohara Y, Minematsu K, Amano T, Ohashi Y: Modified Rankin scale with expanded guidance scheme and interview questionnaire: interrater agreement and reproducibility of assessment. Cerebrovasc Dis 21: 271-278, 2006
25. Shinohara Y, Ogawa A, Suzuki N, Katayama Y, Kimura A (eds): [Japanese Guidelines for the Management of Stroke 2009]. Tokyo, Kyowa Kikaku, 2009, p 55 (Japanese)
26. Shinohara Y, Yoshimoto T, Fukuuchi Y, Ishigami S (eds): [Japanese Guidelines for the Management of Stroke 2004]. Tokyo, Kyowa Kikaku, 2004, p 41 (Japanese)
27. Steinke W, Ley SC: Lacunar stroke is the major cause of progressive motor deficits. Stroke 33: 1510-1516, 2002
28. Uchiyama S: [Antithrombotic therapy in acute ischemic stroke]. Rinsho Shinkeigaku 46: 844-846, 2006 (Japanese)
29. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607, 1988
30. Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC: Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 62: 393-397, 2005
31. Yasunaga K, Mase K: Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 35: 1189-1192, 1985